Use of a gonadotropin-releasing hormone agonist analogue for treatment of cyclic auditory dysfunction.
A patient with cyclic luteal phase high-frequency hearing loss is described. This was documented by pre- and post-menstrual audiograms indicating a 40-dB hearing loss in the luteal phase. This had been long-standing and was resistant to oral contraceptive therapy. A gonadotropin-releasing hormone agonist (nafarelin) was used to inhibit ovarian function and was successful in preventing loss of hearing for the 6-month treatment period.